# Dossier: DAXOR CORPORATION

## SBIR Award Details

**Award Title:** N/A

**Amount:** $1,649,997.00

**Award Date:** 2024-08-06

**Branch:** DHA

## AI-Generated Intelligence Summary

**Company Overview:**

DAXOR CORPORATION (NYSE: DXRA) is a biotechnology company focused on blood volume measurement technology. Their core mission is to improve patient outcomes through accurate and individualized blood volume management, addressing the widespread underdiagnosis and mismanagement of blood volume imbalances, particularly in critically ill patients, those with heart failure, and those undergoing complex surgeries. DAXOR's unique value proposition lies in their BVA-100 Blood Volume Analyzer, the only FDA-cleared diagnostic device for providing direct, quantitative measurements of a patient's blood volume and its components (plasma volume and red blood cell volume), enabling clinicians to make more informed decisions regarding fluid administration, diuretic therapy, and other interventions. The company aims to replace subjective assessments with objective, data-driven insights.

**Technology Focus:**

* BVA-100 Blood Volume Analyzer:\*\* This is DAXOR's flagship product, an automated instrument that directly measures a patient's total blood volume, plasma volume, and red blood cell volume using a patented modified indicator dilution technique.
* DAXOR’s proprietary algorithm:\*\* This algorithm analyzes the data generated by the BVA-100 and provides clinically relevant parameters, including absolute blood volume, relative blood volume deficit/excess, and other key hemodynamic indicators.

**Recent Developments & Traction:**

* FDA 510(k) Clearance for BVA-100 with Updated Software (January 2023):\*\* DAXOR announced FDA clearance for a software update to the BVA-100, further enhancing its usability and accuracy.
* Expansion of Commercial Partnerships (Ongoing):\*\* While specific details are scarce, DAXOR continues to build commercial relationships with hospitals and clinics to expand the adoption of the BVA-100. News and press releases suggest growing adoption in specialized cardiology and critical care settings.
* Continued Research and Publications:\*\* DAXOR has been actively involved in supporting and publishing research highlighting the clinical utility of blood volume analysis in various medical conditions. Recent publications emphasize the benefits of BVA in optimizing fluid management in heart failure patients.

**Leadership & Team:**

* Dr. Joseph Feldschuh (CEO & President):\*\* Dr. Feldschuh is a medical doctor and has been the CEO and President of DAXOR for an extended period. He appears to be the driving force behind the company's strategy and vision.
* Michael Feldschuh (CFO):\*\* Michael Feldschuh is the Chief Financial Officer.

**Competitive Landscape:**

* ICU Medical (Fluid Management Systems):\*\* ICU Medical offers a range of fluid management and hemodynamic monitoring solutions. DAXOR differentiates itself through its direct measurement of blood volume, offering a more precise and individualized assessment compared to indirect estimations used by some competitors.
* Edwards Lifesciences (Hemodynamic Monitoring):\*\* Edwards Lifesciences is a significant player in hemodynamic monitoring, but their focus tends to be on pressure-based and flow-based measurements, not direct blood volume.

**Sources:**

1. [https://daxor.com/](https://daxor.com/)

2. [https://www.sec.gov/edgar/browse/?CIK=0000869016](https://www.sec.gov/edgar/browse/?CIK=0000869016) (DAXOR’s SEC filings)

3. [https://daxor.com/blood-volume-analyzer/](https://daxor.com/blood-volume-analyzer/)